Loading...
XPAR
NANO
Market cap228mUSD
Jun 10, Last price  
4.30EUR
1D
4.88%
1Q
42.86%
Jan 2017
-72.15%
IPO
-36.01%
Name

Nanobiotix SA

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.92%
Rev. gr., 5y
203.88%
Revenues
-12m
L
1,360,31474,153184,938967,500265,5431,558,101251,968116,00068,00050,00010,0004,776,00030,058,000-11,609,000
Net income
-68m
L+71.62%
-5,246,579-5,330,896-8,144,920-9,556,525-17,003,084-21,880,511-26,143,249-29,896,000-50,915,000-33,623,000-47,004,000-57,043,000-39,700,000-68,132,000
CFO
-20m
L+56.71%
-4,873,240-3,785,750-6,830,566-8,564,825-16,820,489-18,283,766-21,032,806-25,985,000-41,169,000-27,538,000-29,872,000-37,104,000-12,476,000-19,551,000
Earnings
Sep 16, 2025

Profile

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
URL
https://www.nanobiotix.com
IPO date
Oct 29, 2012
Employees
102
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
(11,609)
-138.62%
30,058
529.36%
4,776
47,660.00%
Cost of revenue
60,600
60,057
51,101
Unusual Expense (Income)
NOPBT
(72,209)
(29,999)
(46,325)
NOPBT Margin
622.01%
Operating Taxes
101
120
10
Tax Rate
NOPAT
(72,310)
(30,119)
(46,335)
Net income
(68,132)
71.62%
(39,700)
-30.40%
(57,043)
21.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
60,154
BB yield
Debt
Debt current
4,924
5,022
4,560
Long-term debt
50,208
50,625
54,138
Deferred revenue
Other long-term liabilities
28,208
325
270
Net debt
5,395
(19,636)
17,310
Cash flow
Cash from operating activities
(19,551)
(12,476)
(37,104)
CAPEX
(846)
(328)
(93)
Cash from investing activities
(955)
(349)
138
Cash from financing activities
(5,135)
46,771
(5,651)
FCF
(71,741)
(29,106)
(45,269)
Balance
Cash
49,737
75,283
41,388
Long term investments
Excess cash
50,317
73,780
41,149
Stockholders' equity
(378,218)
(314,358)
(282,577)
Invested Capital
391,625
363,404
302,375
ROIC
ROCE
EV
Common stock shares outstanding
47,265
36,928
34,852
Price
Market cap
EV
EBITDA
(70,588)
(28,486)
(44,825)
EV/EBITDA
Interest
8,086
7,982
5,837
Interest/NOPBT